11 Most Undervalued Long Term Stocks to Buy According to Hedge Funds

9. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Forward P/E: ~14.5x

5-year Revenue Growth: ~13.9%

Number of Hedge Fund Holders: 66

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s stock to $640 from $600, while keeping an “Outperform” rating, as reported by The Fly. As per the analyst, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s healthy Q2 2025 print reflects a step of progress in the longer journey to regain the competitive positioning of its EYLEA franchise, even though clinical and regulatory missteps have been weighing on the shares.

According to the firm, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s core emphasis for H2 2025 remains commercial execution and clearance of regulatory hurdles with approval of key EYLEA HD label expansions. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) saw a healthy Q2 2025, characterized by strong growth in US sales of EYLEA HD and global sales of Dupixent and Libtayo, together with multiple regulatory approvals. Notably, in June 2025, the FDA approved Dupixent for treating adults with bullous pemphigoid.

Longleaf Partners, managed by Southeastern Asset Management, released its Q2 2025 investor letter. Here is what the fund said:

“Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Healthcare company Regeneron detracted in the quarter. While we have followed the company for a long time, Regeneron is a newer holding. The company has a net cash balance sheet and great owner-partners. Unlike most others in its industry, it has sworn off large M&A, and it recently began a share repurchase program. This quarter’s performance was disappointing to the market due to a significant focus on Eylea, a retinal disease medication which constitutes less than 20% of the company’s valuation. Later in the quarter, the company also had a negative clinical trial outcome for a potential new product. We took the opportunity to increase our position on the share price weakness when the stock price decline far outpaced the value per share impacts of these items.”